Jay Bradner: leading Novartis into age of digitally-enabled discovery
Jay Bradner, head of Novartis’ drug discovery, talks to pharmaphorum about the firm’s drive to transform itself into ‘a medicine and data science company’.
Jay Bradner, head of Novartis’ drug discovery, talks to pharmaphorum about the firm’s drive to transform itself into ‘a medicine and data science company’.
Cutting-edge technologies are increasingly improving pharma’s R&D processes.
Artificial Intelligence (AI), big data and genomics are coming together to revolutionise drug discovery and development.